Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Docetaxel
Related studies linked through entity extraction aliases.
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
- Status
- COMPLETED
- Phase
- PHASE1
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE3
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
- Status
- TERMINATED
- Phase
- PHASE3
A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.
- Status
- UNKNOWN
- Phase
- PHASE3
A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
- Status
- COMPLETED
- Phase
- PHASE3
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2